iPSC– tag –
-
Chronic Exposure to Chlorate at Regulatory Safety Limits Induces p21/p16-Mediated Neuronal Senescence and Parkinsonian Decline in iPSC-Derived Neurons
PubMed International Overview This research reports that chronic exposure to chlorate at concentrations within regulatory safety limits accelerates neuronal senescence in human iPSC-derived dopaminergic neurons, leading to Parkinsonian-l... -
Rapid Rise of iPSC-Based Therapies: Manufacturing Challenges and FUJIFILM Cellular Dynamics’ Automation Solutions
Contract Pharma International Overview iPSC-based therapies are rapidly advancing as a renewable, standardized source for allogeneic treatments and scalable solutions across various indications. However, manufacturing poses challenges in... -
NueCell Bio Launches 26,300-Square-Foot Cell Therapy Development Facility to Scale CDMO Services in San Diego
PharmaSource USA Overview NueCell Bio has launched as a dedicated cell therapy science and development services company, opening a 26,300-square-foot facility in San Diego to support translational development, process development, analyt... -
IPS HEART Secures FDA Rare Pediatric Disease Designation for Muscular Dystrophy-Associated Cardiomyopathies, Accelerating Cardiac Regenerative Medicine Development
BioSpace USA Overview IPS HEART has received Rare Pediatric Disease Designation (RPDD) from the U.S. FDA for its iPSC-derived therapeutic candidate for muscular dystrophy-associated cardiomyopathies. This marks the company's 8th FDA regu... -
CEA-Targeted CAR-NK Cells Derived from iPSCs Demonstrate Potent Anti-Tumor Activity Against Colorectal Cancer
Frontiers in Immunology Unknown Overview A new study reports that chimeric antigen receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) exhibit potent anti-tumor activity against colorectal cancer. These CEA-target... -
China’s Xellsmart Secures FDA Fast Track for Off-the-Shelf Stem Cell Therapy XS411 in Parkinson’s Disease, Demonstrating Efficacy in Early-Stage Patients in Chinese Phase 1/2 Trial
Endpoints News China Overview China-based Xellsmart's off-the-shelf stem cell therapy, XS411, for Parkinson's disease, has received FDA Fast Track designation. XS411 aims to replace lost dopamine-producing neurons and restore neurologica... -
Keio University Publishes Long-Term Safety Data in Nature Medicine for iPSC-Derived Neural Stem Cell Transplant in Spinal Cord Injury: No Tumor Formation or Serious Adverse Events Over Four Years
OmniGenix Japan Overview A research team at Keio University has published groundbreaking long-term safety data in Nature Medicine from the world's first clinical study of iPSC-derived neural stem cell transplantation for spinal cord inju... -
Japan Marks 20th Anniversary of iPSC Discovery with World’s First Regenerative Medicine Product Approvals: Myocardial Cell Sheets for Severe Heart Failure and Neural Progenitor Cell Transplants for Parkinson’s Disease
Japan Science and Technology Agency (JST) Japan Overview Twenty years after Professor Shinya Yamanaka's discovery of iPS cells at Kyoto University in 2006, Japan achieved a global first with the approval of iPSC-derived regenerative medi... -
Aspen Neuroscience’s Personalized Cell Therapy Sasineprocel (ANPD001) Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Parkinson’s Disease
Longevity.Technology USA Overview Aspen Neuroscience announced that sasineprocel (ANPD001), its personalized cell therapy for Parkinson's disease, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA... -
Century Therapeutics Targets Q4 2026 IND Submission for iPSC-Derived CNTY-813 in Type 1 Diabetes, Advances CAR-iT Cell Therapy CNTY-308 Towards Clinical Trials This Year
Century Therapeutics, Inc. (Press Release) USA Overview Century Therapeutics announced that it has completed its pre-IND meeting with the FDA for CNTY-813, an iPSC-derived cell therapy for Type 1 diabetes, targeting an Investigational Ne...
